Back to search results

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Acute Leukemia of Ambiguous Lineage · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic Syndrome

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

    Contact: Study coordinator (Filippo Milano, MD, PhD) · fmilano@fredhutch.org · 206-667-5925
    Contact: Principal Investigator (Filippo Milano, MD, PhD)
Study leads

  • Filippo Milano, MD, PhD

    Principal Investigator

    Fred Hutch/University of Washington Cancer Consortium

View source on ClinicalTrials.gov(opens in a new tab)